Patent · US Active

Radio-pharmaceutical complexes

US11260136B2 · kind B2 · utility

0Cited by

3References

9Claims

0Family size

Assignees

Bayer Pharma Aktiengesellschaft · DE
Bayer AS · NO

Inventors

Lars Linden · Mülheim an der Ruhr, DE
Alan Cuthbertson · San Jose, US

Key dates

Filing date	Mar 20, 2017
Grant date	Mar 1, 2022
Priority date	—
Expiry date	Mar 20, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.